The latest new contracts, like Numab Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Nov 15, 2024•over 1 year ago
Contract Type
partnership
HorgenBiotechnologyHealth CareTherapeutics
Description
Numab Therapeutics AG and Kaken Pharmaceutical Co., Ltd. announced a new collaboration and option agreement to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD). Under the terms of the agreement, Kaken has obtained an option to acquire commercial rights to ND081 for certain key Asian territories in exchange for funding preclinical and clinical development up to Phase 2a proof of concept.
Company Information
Company
Numab Therapeutics
Location
Horgen, Zurich, Switzerland
About
Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits.
Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.
HorgenBiotechnologyHealth CareTherapeutics